Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of telomeres ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback